napabucasin + cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-drug Interactions
Conditions
Drug-drug Interactions
Trial Timeline
Jun 30, 2017 → Jan 23, 2018
NCT ID
NCT03411122About napabucasin + cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate
napabucasin + cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate is a phase 1 stage product being developed by Sumitomo Pharma for Drug-drug Interactions. The current trial status is completed. This product is registered under clinical trial identifier NCT03411122. Target conditions include Drug-drug Interactions.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03411122 | Phase 1 | Completed |
Competing Products
15 competing products in Drug-drug Interactions